focus -WSS

focus

author：hotspot 2025-09-29 01:38:37 - browse：4

Sage Therapeutics, a biotech developing an experimental treatment for postpartum depression, this week trumpeted strong results from a clinical trial, which cheered investors and pushed up its stock price. But outside the lab, the company’s aggressive efforts to raise awareness of postpartum depression have proved divisive.

The campaign’s message: “When it comes to postpartum depression, silence sucks.” It features close-up photos of distressed, tearful women who can’t speak — because they have pacifiers stuck in their mouths.

The images have been plastered on bus stops, buses, conference booths, and on a dedicated website. The ads don’t specifically mention Sage’s drug, which still needs further testing before the company can bring it to the Food and Drug Administration for possible approval. Instead, they urge women to talk “openly and honestly” about postpartum depression. An estimated 600,000 women in the U.S. alone experience symptoms, which range from insomnia and irritability to difficulty bonding with their baby.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

focus

WSS

When waiting feels immoral: Empathy in the emergency department

Medicare Advantage enrollment hits roughly 33.4 million

Chris Christie meets with Zelenskyy during Ukraine trip

Flint parents haunted by uncertainty, fears of lead poisoning

Surprise medical billing ban raises prices elsewhere

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

focus

focus

entertainment

In Memoriam: Notable people who died in 2023

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

Heart attack and stroke risk calculators need revising

H.R. 3 is the wrong path to lower drug costs

Alkermes shareholders re

How I helped Pfizer think through the ethics of Viagra

After affirmative action ruling, medical educators look to 'holistic review'

Medicare slashes safety net hospital payments by nearly $1 billion

Wikipedia

In 'major milestone,' FDA approves first cell therapy for solid tumors

FDA approves Sage Therapeutics’ rapid

Obamacare plans could cover weight loss drugs

WATCH: Why do our ears pop?

Flagship Pioneering startup Sonata Therapeutics lays off 21

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

focus

focus

focus

entertainment